SOUTH SAN FRANCISCO, Calif., April 29 Anesiva,Inc. (Nasdaq: ANSV) today announced a new exclusive Zingo(TM) marketing anddistribution agreement, with Green Vision Company, for several Middle Easterncountries. Zingo (lidocaine hydrochloride monohydrate) powder intradermalinjection system is approved in the U.S. to provide topical local analgesiaprior to peripheral IV insertions or blood draws in children three to 18 yearsof age.
Green Vision is a pharmaceutical company headquartered in Qatar. Theagreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabiaand United Arab Emirates. Green Vision will be responsible for obtaining andmaintaining product registrations in the licensed territories, as well assales and marketing in the region. Terms of the agreement include an upfrontpayment, regulatory and sales milestones and royalty payments.
"This agreement further extends the potential markets for Zingo, aneedle-free, local analgesic with a rapid onset of action, prior to peripheralvenous access procedures in children, and is further validation of the unmetneed Zingo addresses," said John P. McLaughlin, Anesiva's chief executiveofficer.
Zingo(TM) is an easy-to-administer, single-use, needle-free system thatdelivers sterile lidocaine powder to provide topical, local anesthesia toreduce the pain associated with peripheral IV insertions or blood draws.Zingo's rapid onset of action allows intravenous line placement orvenipuncture to begin one to three minutes after administration. Zingo isapproved in the U.S. to reduce the pain associated with peripheral IVinsertions or blood draws in children three to 18 years of age. In clinicaltrials, the most common adverse events with Zingo were redness (erythema), reddots (petechiae) and swelling (edema). In March 2008, Anesiva submitted asupplemental new drug application (sNDA) to expand the label indication forZingo to include adults, based on a positive Phase 3 trial in nearly700 patients.
About Anesiva and its Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to bethe leader in the development and commercialization of novel pharmaceuticalproducts for pain management. The company has one FDA-approved product,Zingo(TM), for the reduction of pain associated with peripheral venous accessprocedures in children ages three to 18. The second product in Anesiva'spipeline, Adlea(TM), has been shown to reduce pain after only a singleadministration for weeks to months in multiple settings mid-stage clinicaltrials for site-specific, acute and chronic, moderate-to-severe pain. Anesivais based in South San Francisco, CA, USA. For more information aboutAnesiva's leadership in the development of products for pain management, andan overview of the clinical challenges being addressed by its productcandidates, go to http://www.anesiva.com.
This press release includes "forward-looking statements" within themeaning of the safe harbor provisions of the United States Private SecuritiesLitigation Reform Act of 1995. Words such as "expect," "estimate," "project,""budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could,""should," "believes," "predicts," "potential," "continue," and similarexpressions are intended to identify such forward-looking statements.Forward-looking statements in this press release include matters that involveknown and unknown risks, uncertainties and other factors that may cause actualresults, levels of activity, performance or achievements to differ materiallyfrom results expressed or implied by this press release. Such risk factorsinclude, among others: the timing and results of our clinical trials, whetherAnesiva is able to manufacture its products on commercially reasonable terms,and the degree to which Zingo gains market acceptance.